-
Mashup Score: 5
A new study conducted by an international research team has identified new susceptibility regions that are associated with renal cell carcinoma development risk.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4CheckMate-67T: Subcutaneous Nivolumab Shows Comparable Results to IV, Reduces Treatment Burden in RCC - Saby George - 4 day(s) ago
Dan George discusses the CheckMate-67T study with Saby George, a phase three trial comparing intravenous and subcutaneous administration of nivolumab in treatment-refractory kidney cancer patients. Conducted across 73 centers in 17 countries, this trial aimed to assess if subcutaneous nivolumab could match the systemic effects of its IV counterpart. Meeting its co-primary pharmacokinetic…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5CheckMate-214 at 8 Years: Nivolumab + Ipilimumab Shows Durable Survival Benefit in Advanced RCC - Nizar Tannir - 11 day(s) ago
Pedro Barata and Nizar Tannir delve into the eight-year results of the CheckMate-214 trial, showcasing the sustained efficacy of ipilimumab and nivolumab (ipi/nivo) in advanced renal cell carcinoma (RCC). Dr. Tannir highlights the treatment’s enduring hazard ratio and significant mortality risk reduction, emphasizing the notable longevity and durability of patient responses. Their conversation…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Advances in Therapeutic Strategies for Advanced Renal Cell Carcinoma: A Comprehensive Review - 22 day(s) ago
Advanced renal cell carcinoma (RCC), advanced RCC management, Adjuvant Therapies for ccRCC, HIF-2α inhibitor belzutifan, First-line treatment of advanced unresectable ccRCC, FDA approval for treating advanced RCC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances in therapeutic strategies for advanced #RCC: a comprehensive review. @PBarataMD discusses current therapeutic approaches for pts with advanced RCC, including clear cell and other histotypes and the role of (neo)adjuvant treatment and biomarkers > https://t.co/nTEpK3ly7m https://t.co/Qg71JYSk6H
-
-
Mashup Score: 1TPST-1120 Plus Nivolumab Offers New Treatment Potential in RCC - 23 day(s) ago
The novel PPAR-α inhibitor TPST-1120 shows promise for solid tumors, including renal cell carcinoma, as monotherapy and in combination with nivolumab.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Unmeet Needs in Non-Clear Cell Renal Cell Carcinoma - 26 day(s) ago
Dr. Plimack shares her insights on some unmeet needs and challenges when treating non-clear cell renal cell carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Unmeet Needs in Non-Clear Cell Renal Cell Carcinoma - 1 month(s) ago
Dr. Plimack shares her insights on some unmeet needs and challenges when treating non-clear cell renal cell carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Chromophobe Renal Cell Carcinoma - Beyond the Abstract - 1 month(s) ago
renal cell carcinomas (vhRCCs), clear cell renal cell carcinoma (ccRCC), renal cell carcinoma (RCC), kidney cancer, vacuolar ATPase (v-ATPase), Tuberous Sclerosis Complex (TSC), mechanistic target of rapamycin complex 1 (mTORC1), innate lymphoid cells type 1 (ILC1s), mTOR pathways, PTEN mutations, Birt-Hogg-Dube syndrome (BHD).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Delve into the intricate world of Chromophobe #RCC with our latest review! Discover the unique pathogenic mechanisms, potential therapeutic targets, and challenges in advancing research and treatment with Elizabeth Henske and Melissa Daou @BrighamWomens > https://t.co/AevweMyNAH https://t.co/Q3Fi9n6al1
-
-
Mashup Score: 0Advances in Therapeutic Strategies for Advanced Renal Cell Carcinoma: A Comprehensive Review - 1 month(s) ago
Advanced renal cell carcinoma (RCC), advanced RCC management, Adjuvant Therapies for ccRCC, HIF-2α inhibitor belzutifan, First-line treatment of advanced unresectable ccRCC, FDA approval for treating advanced RCC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances in therapeutic strategies for advanced #RCC: a comprehensive review. @PBarataMD discusses current therapeutic approaches for pts with advanced RCC, including clear cell and other histotypes and the role of (neo)adjuvant treatment and biomarkers > https://t.co/nTEpK3ly7m https://t.co/Qg71JYSk6H
-
-
Mashup Score: 4
Over the last 20 years, standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have progressed from cytokines and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) to immune checkpoint inhibition (ICI)–based treatment. The availability of these , however, can vary worldwide.
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet-
Chatted w/ @medpagetoday on our @JCOGO_ASCO study on the evolution of systemic #RCC therapy in Canada, highlighting the levers in public health care systems https://t.co/mhEQDRIGf3 Yeoman effort by @luisamcardenas w/ @UroOncMD @DrDanielHeng @nbasappaCCI @SiTanguay & many! 👏 🙏 https://t.co/vcYJtKrKIi https://t.co/3dttBJAVuD
-
🧬 A recent study identified new susceptibility regions that are associated with the risk of developing #RCC. 🧠 Find Out More: https://t.co/H9tLDEkIJk https://t.co/jk8FybLLXD